BackAileron Therapeutics Overview

Aileron Therapeutics Common Stock

Latest common stock for ALRN: $170K.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$172000.00
31.30% YoYΔ $41000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Aileron Therapeutics Common Stock History

Loading

Aileron Therapeutics vs. peers: Common Stock Comparison

Loading

Aileron Therapeutics Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Aileron Therapeutics (ALRN) FAQ

Aileron Therapeutics (ALRN) currently reports a common stock of $170K as of June 2026. That compares with $130K in the prior-year period — up 31.3% year over year. Use the charts on this page to explore Aileron Therapeutics's common stock history and peer comparisons.

Aileron Therapeutics's common stock increased from $130K to $170K — a 31.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aileron Therapeutics reported $170K in common stock as of June 2026. That compares with $130K in the prior-year period — up 31.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $170K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aileron Therapeutics, and consider following ALRN for alerts when major investors trade the stock.

Aileron Therapeutics is classified in the Healthcare sector. On common stock, it currently shows $170K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALRN with unrelated industries.